---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Safety questions"
description: "Safety questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Warnings. Questions: What side effects were reported with Trelegy in the IMPACT COPD trial? What side effects were reported with Trelegy in the FULFIL trial? What are the most common side effects of Trelegy for COPD? What are the long-term side effects of Trelegy for COPD? 4 further questions follow. 8 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Safety questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Safety questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Safety](https://www.evicenter.com/medical-information/trelegy-ellipta/safety).

## Side effects

<a id="trelegy-impact-side-effects"></a>

### What side effects were reported with Trelegy in the IMPACT COPD trial?

> “From the 52-week IMPACT trial, the most commonly reported adverse events with ≥5% incidence were<sup>1</sup>
>
> Adverse Events
>
>
>
> TRELEGY 100
> (n=4151)
> %
>
>
>
> BREO 100
> (n=4134)
> %
>
>
>
> ANORO
> (n=2070)
> %
>
>
>
>
> Viral URTI
>
>
>
> 13
>
>
>
> 12
>
>
>
> 11
>
>
>
>
> COPD<sup>§</sup>
>
>
>
> 11
>
>
>
> 11
>
>
>
> 13
>
>
>
>
> URTI
>
>
>
> 7
>
>
>
> 7
>
>
>
> 6
>
>
>
>
> Pneumonia
>
>
>
> 7
>
>
>
> 6
>
>
>
> 4
>
>
>
>
> Headache
>
>
>
> 6
>
>
>
> 5
>
>
>
> 5
>
>
>
>
> <sup>§</sup>Signs, symptoms, or progression of COPD are more severe than expected for the patient's condition.”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=From%20the%2052%2Dweek%20IMPACT%20trial%2C,expected%20for%20the%20patient%27s%20condition.)

> “In the 52-week IMPACT trial, the incidence of pneumonia (Adverse Events of Special Interest) was<sup>1</sup>
>
> Adverse Events of Special Interest
>
>
>
> TRELEGY 100
> (n=4151)
> %
>
>
>
> BREO 100
> (n=4134)
> %
>
>
>
> ANORO
> (n=2070)
> %
>
>
>
>
> Pneumonia
>
>
>
> 8
>
>
>
> 7
>
>
>
> 5”

Source: [TRELEGY ELLIPTA: IMPACT Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/impact-study/#:~:text=In%20the%2052%2Dweek%20IMPACT%20trial%2C,5)

Note: The table text lists each row's values in the header order: TRELEGY 100 (n=4151), BREO 100 (n=4134), ANORO (n=2070), as percentages. Pneumonia counted as an adverse event of special interest was 8% for TRELEGY 100.

<a id="trelegy-fulfil-side-effects"></a>

### What side effects were reported with Trelegy in the FULFIL trial?

> “From the 24-week, non-US FULFIL trial, the most commonly reported adverse events with ≥2% incidence were<sup>1</sup>:
>
> Adverse Events	
>
> TRELEGY 100
>
> (n=911)
>
> %
>
>
>
> SYMBICORT TURBUHALER
> 400/12* (n=899)
>
> %
>
>
> Nasopharyngitis	7	5
> Headache	5	6
> URTI	2	2
> COPD<sup>§</sup>	2	3
> Back pain	2	2
> Arthralgia	2	1
> Pneumonia	2	<1
> Pharyngitis	2	1”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=From%20the%2024%2Dweek%2C%20non%2DUS%20FULFIL,1)

On the page, select: FULFIL study description1,4

> “In the non-US FULFIL trial: Incidence of pneumonia (Adverse Events of Special Interest)<sup>1</sup>
>
>
>
> TRELEGY 100
>
> %
>
>
>
> SYMBICORT
>
> TURBUHALER
>
> 400/12*
>
> %
>
>
>
>
>      24 Weeks
>
>
>
> (n=911)
>
> 2.2
>
>
>
> (n=899)
>
> 0.8
>
>
>
>
>      52 Weeks
>
>      (extension population)
>
>
>
> (n=210)
>
> 1.9
>
>
>
> (n=220)
>
> 1.8”

Source: [TRELEGY ELLIPTA: FULFIL Study Data, captured 2026-11-14](https://www.trelegyhcp.com/copd/fulfil-study/#:~:text=In%20the%20non%2DUS%20FULFIL%20trial%3A,1.8)

On the page, select: FULFIL study description1,4

Note: Each row lists TRELEGY 100 first and SYMBICORT TURBUHALER 400/12 second, as percentages. In the pneumonia table the 52-week row covers the extension population. SYMBICORT TURBUHALER 400/12 is a non-US budesonide/formoterol formulation.

<a id="trelegy-common-side-effects"></a>

### What are the most common side effects of Trelegy for COPD?

> “In subjects with COPD, the most common adverse reactions (≥1% and more common than placebo + FF/VI) reported in two 12-week clinical trials with UMEC + FF/VI, the components of TRELEGY, (and placebo + FF/VI) were: headache, 4% (3%); back pain, 4% (2%); dysgeusia, 2% (<1%); diarrhea, 2% (<1%); cough, 1% (<1%); oropharyngeal pain, 1% (0%); and gastroenteritis, 1% (0%).”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=In%20subjects%20with%20COPD%2C%20the,%280%25%29%3B%20and%20gastroenteritis%2C%201%25%20%280%25%29.)

> “COPD: Most common adverse reactions (incidence ≥1%) are upper 
> respiratory tract infection, pneumonia, bronchitis, oral candidiasis, 
> headache, back pain, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, 
> dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis, 
> oropharyngeal pain, cough, and dysphonia. (6.1)”

Source: [TRELEGY ELLIPTA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=1)

Note: The first passage gives rates from two 12-week trials of umeclidinium added to fluticasone furoate/vilanterol, with the placebo + FF/VI rate in parentheses. The second is the label summary, which includes the 52-week trial.

<a id="trelegy-long-term-side-effects"></a>

### What are the long-term side effects of Trelegy for COPD?

> “In addition to the adverse reactions shown in table above, adverse reactions occurring in ≥1% of the subjects with COPD treated with TRELEGY 100/62.5/25 (n=4151) for up to 52 weeks also included URTI, pneumonia, bronchitis, oral candidiasis, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, constipation, UTI, and dysphonia.”

Source: [TRELEGY ELLIPTA: Adverse Reactions, captured 2026-11-14](https://www.trelegyhcp.com/adverse-reactions/#:~:text=In%20addition%20to%20the%20adverse,rhinitis%2C%20constipation%2C%20UTI%2C%20and%20dysphonia.)

> “The incidence of adverse reactions in the long-term trial were consistent with those in Trials 1 
> and 2.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 14, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=14)

Note: The label's warnings on bone mineral density, glaucoma, and cataracts concern long-term ICS use; see the bone loss and glaucoma questions.

## Warnings

<a id="trelegy-pneumonia"></a>

### Does Trelegy increase the risk of pneumonia in COPD?

> “Lower respiratory tract infections, including pneumonia, have been reported following use of ICS, like fluticasone furoate. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD, as clinical features of pneumonia and exacerbations frequently overlap.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Lower%20respiratory%20tract%20infections%2C%20including,pneumonia%20and%20exacerbations%20frequently%20overlap.)

> “In a 52-week trial of subjects with COPD (N = 10,355), the incidence of pneumonia was 8% for 
> TRELEGY ELLIPTA 100/62.5/25 mcg (n = 4,151), 7% for fluticasone furoate/vilanterol 
> 100/25 mcg (n = 4,134), and 5% for umeclidinium/vilanterol 62.5/25 mcg (n = 2,070). Fatal 
> pneumonia occurred in 12 of 4,151 patients (0.35 per 100 patient-years) receiving TRELEGY 
> ELLIPTA 100/62.5/25 mcg; 5 of 4,134 patients (0.17 per 100 patient-years) receiving 
> fluticasone furoate/vilanterol 100/25 mcg; and 5 of 2,070 patients (0.29 per 100 patient-years) 
> receiving umeclidinium/vilanterol 62.5/25 mcg.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=7)

> “Increased risk of pneumonia in patients with COPD. Monitor patients for 
> signs and symptoms of pneumonia.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 1, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=1)

Note: The 52-week trial is IMPACT (Trial 3 of the Prescribing Information).

<a id="trelegy-heart-effects"></a>

### Can Trelegy cause heart problems in COPD?

> “Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, TRELEGY may need to be discontinued. TRELEGY should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Vilanterol%20can%20produce%20clinically%20significant,insufficiency%2C%20cardiac%20arrhythmias%2C%20and%20hypertension.)

> “In a 52-week trial of subjects with COPD, the exposure-adjusted rates for any on-treatment 
> major adverse cardiac event, including non-fatal central nervous system hemorrhages and 
> cerebrovascular conditions, non-fatal myocardial infarction (MI), non-fatal acute MI, and 
> adjudicated on-treatment death due to cardiovascular events, was 2.2 per 100 patient-years for 
> TRELEGY ELLIPTA (n = 4,151), 1.9 per 100 patient-years for fluticasone furoate/vilanterol 
> 100/25 mcg (n = 4,134), and 2.2 per 100 patient-years for umeclidinium/vilanterol 62.5/25 mcg 
> (n = 2,070). Adjudicated on-treatment deaths due to cardiovascular events occurred in 20 of 
> 4,151 patients (0.54 per 100 patient-years) receiving TRELEGY ELLIPTA; 27 of 4,134 patients 
> (0.78 per 100 patient-years) receiving fluticasone furoate/vilanterol; and 16 of 2,070 patients 
> (0.94 per 100 patient-years) receiving umeclidinium/vilanterol.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 10, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=10)

Note: The 52-week trial is IMPACT (Trial 3 of the Prescribing Information).

<a id="trelegy-bone-density"></a>

### Does Trelegy cause bone loss in COPD?

> “Decreases in bone mineral density (BMD) have been observed with long-term administration of 
> products containing ICS. The clinical significance of small changes in BMD with regard to 
> long-term consequences such as fracture is unknown. Patients with major risk factors for 
> decreased bone mineral content, such as prolonged immobilization, family history of 
> osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of 
> drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored 
> and treated with established standards of care. Since patients with COPD often have multiple risk 
> factors for reduced BMD, assessment of BMD is recommended prior to initiating TRELEGY 
> ELLIPTA and periodically thereafter. If significant reductions in BMD are seen and TRELEGY 
> ELLIPTA is still considered medically important for that patient’s COPD therapy, use of therapy 
> to treat or prevent osteoporosis should be strongly considered.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 11, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=11)

<a id="trelegy-acute-exacerbation"></a>

### Can Trelegy be started while COPD is rapidly worsening?

> “TRELEGY should NOT be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=TRELEGY%20should%20NOT%20be%20initiated,episodes%20of%20COPD%20or%20asthma.)

> “TRELEGY ELLIPTA has not been 
> studied in subjects with acutely deteriorating COPD or asthma. The initiation of TRELEGY 
> ELLIPTA in this setting is not appropriate.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=6)

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines)
